Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05945069
Other study ID # LUM-VBU-TRILIFT-23-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2023
Est. completion date February 15, 2024

Study information

Verified date July 2023
Source Lumenis Be Ltd.
Contact Yair Manor, Ph.D.
Phone +972-52-376-3416
Email yair.manor@lumenis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To demonstrate that DMSt + RF improves eye blink quality in subjects with dry eye disease


Description:

The purpose of the study is to demonstrate that a combination of DMSt and RF applied on the periocular skin below the lower eyelids improves eye blink quality in subjects with moderate to severe signs and symptoms of dry eye disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date February 15, 2024
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - Subject is able to read, understand and sign an Informed Consent Form (ICF) - 22 or older - Lower lid laxity, as clinically judged with lower lid DT and the snapback test - Moderate to severe OSDI (larger or equal to 23) - TBUT smaller or equal to 5 sec in both eyes Exclusion Criteria: - Abnormally high blink rate, as estimated by the study investigator - Any ocular surgery or eyelid surgery, within 3 months prior to screening - Blepharoptosis - Moderate or Severe Floppy Lid Syndrome - Corneal Dystrophy - Exophthalmos - Thyroid Eye Disease - Ocular Chemical Injury or burn - Limbal Stem Cell Deficiency - Facial Nerve Palsy - Blepharospasm - Hemifacial Spasm - Corneal neuropathy - Pregnant or nursing women - Participation in a different study - Any condition revealed whereby the study investigator deems the subject inappropriate for this study

Study Design


Intervention

Device:
TriLift device
Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids

Locations

Country Name City State
United States Manhattan Face and Eye Cosmetic and Orbital Surgery New York New York

Sponsors (1)

Lead Sponsor Collaborator
Lumenis Be Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Eyelid appearance Biomicroscopy with the slit lamp; normal, mild, moderate, severe 7 weeks after baseline (4 weeks after the 4th treatment)
Other Overall blink quality Subjectively assessed by the study investigator; normal, mildly impaired, moderately impaired, severely impaired 7 weeks after baseline (4 weeks after the 4th treatment)
Other Margin to Reflex Distances MRD1 and MRD2 Distances from the margins of the upper and lower lids to the central corneal reflex, in millimeters 7 weeks after baseline (4 weeks after the 4th treatment)
Other modified Meibomian Gland Score 15 meibomian glands along the lower lid (5 nasal + 5 central + 5 temporal) will be gently expressed with the dedicated expression forceps. Each gland will be scored 0 to 3, as follows: 0 = clear liquid meibum; 1 = cloudy liquid meibum; 2 = inspissated meibum; 3 = blocked). The modified Meibomian Gland score will be evaluated as the sum of scores for these 15 glands. Hence, the minimal value is 0 (all 15 glands express a clear liquid meibum), and the maximal value is 45 (all 15 glands are blocked). A decrease in the modiified Meibomian Gland Score means that the functionality of meibomian glands improved, and that the condition of the patient improved. 7 weeks after baseline (4 weeks after the 4th treatment)
Other Ocular Surface Disease Index Symptoms will be self-evaluated with the Ocular Surface Disease Index questionnaire. Twelve (12) questions will be asked about visual difficulties experienced by the subject during the past week. Each question will be scored 0 (none of the time), 1 (some of the time), 2 (half of the time), 3 (most of the time) or 4 (all the time). The Ocular Surface Disease Index will be calculated as the sum of scores times 25, divided by the number of questions answered. An increase in the Ocular Surface Disease Index means that the symptoms are reduced and that the condition of the patient improved. 7 weeks after baseline (4 weeks after the 4th treatment)
Other Corneal sensitivity Measured with an esthesiometer; device settings: 1 to 6 7 weeks after baseline (4 weeks after the 4th treatment)
Other Blink rate Blinks per minute during a video-watching task 7 weeks after baseline (4 weeks after the 4th treatment)
Other Degree of eyelid closure full, or maximal vertical height of the palpebral fissure measured in mm 7 weeks after baseline (4 weeks after the 4th treatment)
Other Teat Breakup time Time between full blink and first appearance of a break in a fluorescein-stained eye 7 weeks after baseline (4 weeks after the 4th treatment)
Other Adverse events Incidence and type of adverse events Throughout the study and up to 7 weeks after baseline (4 weeks after the 4th treatment)
Other BCVA Best-corrected visual acuity, using an ETDRS chart (20/20, 20/25, 20/32,20/40,20/50,20/63, 20/80, 20/100, 20/200, 20/400, where 20/20 is considered perfect vision and 20/400 is considered legal blindness) At baseline, at 1 week after baseline (immediately before the second treatment), at 2 weeks after baseline (immediately before the third treatment), at 3 weeks after baseline (immediately before the fourth treatment) and at 7 weeks after baseline
Other Pain/Discomfort Pain.discomfort will be self-reported with a visual analog scale (0 to 100), with 0 representing no pain/discomfort and 100 representing intolerable pain/discomfort. A decrease in this visual analog score represents an improvement in the perception of pain/discomfort. Immediately after a treatment session
Primary Impaired blink quality binary (yes/no) variable, based on clinical estimation of the study investigator who will use a combination of two complementary tests (the lower lid distraction test and the snap-back test) to reach a yes/no decision. 7 weeks after baseline (4 weeks after the 4th treatment)
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A